In 1988, the World Health Assembly (WHA) resolved to eradicate polio worldwide. In 2015, only Afghanistan and Pakistan have reported wild poliovirus (WPV) transmission. Timely steps are needed for the containment of WPV and oral poliovirus vaccine (OPV)/Sabin virus materials in laboratories and vaccine manufacturing facilities. On 25 May 2015, all WHO Member States endorsed WHA resolution 68.32 on the full implementation of the Polio Eradication and Endgame Strategic Plan 2013–20183 (the Endgame Plan), and with it, the third Global Action Plan to minimize poliovirus facility-associated risk (GAPIII). All Member States committed to implementing appropriate containment of type 2 WPV (WPV2) in essential facilities by the end of 2015 and of type 2 Sabin poliovirus (Sabin 2) within 3 months of withdrawal of the type 2 component in OPV (OPV2) globally, planned for April 2016. This report summarizes critical steps for essential laboratory and vaccine production facilities that intend to retain materials confirmed to contain or potentially containing type-2 WPV and vaccine-derived poliovirus (VDPV), or OPV/Sabin viruses as of the “Poliovirus type 2 containment period” (Phase II) planned to begin in 2016 and for facilities that may isolate polioviruses after initiation of Phase II. National authorities will need to certify that the essential facilities they host meet the containment requirements described in GAPIII. After certification of WPV eradication, the use of all OPV will cease; final containment of all polioviruses will minimize the risk of reintroduction of poliovirus into a polio-free world.